Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
DEXTERA SURGICAL INC (DXTR)
|
Add to portfolio |
|
|
|
| Price: |
$0.05
| | Metrics |
| OS: |
48.2
|
M
| |
|
|
| Market cap: |
$2.41
|
M
| |
|
|
|
Net cash:
|
$732
|
k
| |
$0.02
|
per share
|
|
EV:
|
$1.67
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($14.0)
|
M
| |
|
|
|
EBIT
|
($14.6)
|
M
| |
|
|
| EPS |
($2.23)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Jun-30-17 | Jun-30-16 | Jun-30-15 | Jun-30-14 | Jun-30-13 | Jun-30-12 | Jun-30-11 | Jun-30-10 |
| Revenues | 3.4 | 4.1 | 3.0 | 3.6 | 3.5 | 3.7 | 13.2 | 4.0 |
| Revenue growth | -15.6% | 35.6% | -17.3% | 3.3% | -4.9% | -72.2% | 232.7% | -59.7% |
| Cost of goods sold | 3.8 | 3.9 | 4.2 | 4.8 | 3.6 | 3.6 | 3.4 | 3.7 |
| Gross profit | -0.4 | 0.2 | -1.2 | -1.2 | -0.1 | 0.0 | 9.9 | 0.3 |
| Gross margin | -11.0% | 3.9% | -41.6% | -32.0% | -3.0% | 1.2% | 74.7% | 7.4% |
| Selling, general and administrative | 7.7 | 9.4 | 10.2 | 8.5 | 6.4 | 6.1 | 5.9 | 5.7 |
| Research and development | 6.6 | 6.3 | 7.3 | 6.9 | 9.1 | 7.2 | 7.5 | 5.4 |
| EBIT | -14.6 | -15.6 | -18.8 | -16.5 | -15.7 | -13.3 | -3.5 | -10.9 |
| EBIT margin | -426.4% | -383.6% | -628.2% | -456.5% | -447.6% | -361.7% | -26.6% | -273.2% |
| Pre-tax income | -17.2 | -16.0 | -19.2 | -17.0 | -16.1 | -13.6 | -3.5 | -11.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Net income | -25.9 | -16.0 | -19.2 | -18.9 | -16.1 | -13.6 | -3.5 | -10.9 |
| Net margin | -757.5% | -394.3% | -641.5% | -522.3% | -461.2% | -368.8% | -26.6% | -274.4% |
| |
| Diluted EPS | ($2.33) | ($1.79) | ($2.16) | ($3.24) | ($0.40) | ($0.44) | ($0.14) | ($0.50) |
| Shares outstanding (diluted) | 11.1 | 8.9 | 8.9 | 5.8 | 40.8 | 30.5 | 25.6 | 21.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|